The US Drug Enforcement Administration (DEA) had granted GW Pharmaceuticals’ request to completely deschedule its cannabis-derived drug, Epidiolex. GW Pharma’s CBD extract previously sat in Schedule V, but as of Monday it’s been completely removed from the federal list of controlled substances — a first for a cannabis drug in the 21st century. See the original […]

The Drug Enforcement Administration placed Epidiolex in Schedule V, marking the first time any drug derived from any part of the cannabis plant has been rescheduled in the U.S. “Marijuana extracts,” including CBD, remain in Schedule I, according to the administration’s 2016 Final Rule. According to the DEA, “Schedule V drugs, substances, or chemicals are […]

GW Pharmaceuticals has revealed the expected consumer price for Epidiolex, the first cannabidiol-based medication to be approved by the FDA, according to a Business Insider report. At a price tag of about $32,500 per year, it won’t be cheap, but company representatives said in a phone call with investors this week that its cost reflects […]

The US Food and Drug Administration announced today, Monday June 25, the approval of the country’s first marijuana-based prescription medication. The drug is called Epidiolex and is a plant-derived oral solution of cannabidiol (CBD)—a chemical component of marijuana that does not cause intoxication or a euphoric “high.” The FDA approved it for use in patients […]

In an open-label observational trial at Primary Children’s hospital, 25 children and teens with treatment-resistant epilepsy who apply to be part of a new drug trial will, will receive Epidiolex, a liquid, purified form of cannabidiol (CBD), a non-psychoactive chemical in marijuana. The primary goal will be to test the tolerability of Epidiolex and the […]